Review Paper:
Biomimetic nanoparticles
for Alzheimer's disease targeting Tau tangles
Agrawal Satyam Kumar and Jain Sushmita Sunil
Res. J. Biotech.; Vol. 20(6); 215-219;
doi: https://doi.org/10.25303/206rjbt2150219; (2025)
Abstract
The progression of Alzheimer's disease (AD) is characterized by the accumulation
of amyloid plaques and tau protein aggregates in the brain. While amyloid plaque
has been the focus of much research and drug development for AD, recent studies
have suggested that tau protein may be a more promising target for therapeutic intervention
because of its more closely associated pathology with cognitive decline and neuronal
death than amyloid plaque. Tau protein is a microtubule-associated protein that
plays a key role in stabilizing the cytoskeleton of neurons. In AD, it gets hyperphosphorylated
and aggregates into neurofibrillary tangles, which disrupt the normal health and
functioning of neurons.
Several approaches have been undertaken to target tau proteins including immunotherapy,
gene therapy and nanotechnology where nanotechnology has been explored as a potential
strategy for its management. One promising area of research is the use of biomimetic
nanoparticles (BNPs) for drug delivery to the brain. BNPs are eco-friendly, sustainable
and better than traditional nanoparticles since they resemble biological things
with increased biocompatibility and stability. However, targeting molecular accessibility,
drug loading capacity and determining long-term safety are the challenges. Thus
to successfully translate these nanofabrications into clinical applications, it
is crucial to address the above adversities.
